Giulia Mazzaschi

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 9

Top Topics

Bioinformatics Analysis

Tyrosine Kinase

Renal Cell Carcinoma

Ejection Fraction

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Matteo Santoni, Javier Molina-Cerrillo, Giorgio Santoni, Elaine T Lam, Francesco Massari, Veronica Mollica, Giulia Mazzaschi, Bernardo Leon Rapoport, Enrique Grande, Sebastiano Buti
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences. Cancers 15 (2) (2023)
Matteo Santoni, Javier Molina-Cerrillo, Giorgio Santoni, Elaine T Lam, Francesco Massari, Veronica Mollica, Giulia Mazzaschi, Bernardo Leon Rapoport, Enrique Grande, Sebastiano Buti
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences. Cancers 15 (2) (2023)
Matteo Santoni, Javier Molina-Cerrillo, Giorgio Santoni, Elaine T Lam, Francesco Massari, Veronica Mollica, Giulia Mazzaschi, Bernardo Leon Rapoport, Enrique Grande, Sebastiano Buti
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences. Cancers 15 (2) (2023)
Giulia Mazzaschi, Alessandro Olivari, Antonio Pavarani, Costanza Anna Maria Lagrasta, Caterina Frati, Denise Madeddu, Bruno Lorusso, Silvia Dallasta, Chiara Tommasi, Antonino Musolino, Marcello Tiseo, Maria Michiara, Federico Quaini, Pellegrino Crafa
Integrated MRI-Immune-Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma. Cancers 14 (13) (2022)
Martina Catalano, Ugo De Giorgi, Marco Maruzzo, Davide Bimbatti, Sebastiano Buti, Giulia Mazzaschi, Giuseppe Procopio, Matteo Santoni, Luca Galli, Raffaele Conca, Laura Doni, Lorenzo Antonuzzo, Giandomenico Roviello
Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma. Biomedicines 10 (10) (2022)
Sebastiano Buti, Melissa Bersanelli, Giulia Mazzaschi, Carlo Cattrini, Matteo Brunelli, Massimo Di Maio
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis. Immunotherapy (2021)
Francesca Trentini, Giulia Mazzaschi, Gianluca Milanese, Claudio Pavone, Denise Madeddu, Letizia Gnetti, Caterina Frati, Bruno Lorusso, Costanza Anna Maria Lagrasta, Roberta Minari, Luca Ampollini, Roberta Eufrasia Ledda, Mario Silva, Nicola Sverzellati, Federico Quaini, Giovanni Roti, Marcello Tiseo
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients. Tumori (2021)
Melissa Bersanelli, Giulia Mazzaschi, Patrizia Giannatempo, Daniele Raggi, Elena Farè, Maruzzo Marco, Umberto Basso, Ugo De Giorgi, Francesca Vignani, Giuseppe Luigi Banna, Marco Stellato, Rosa Tambaro, Emanuele Naglieri, Tania Losanno, Giuseppe Procopio, Sandro Pignata, Andrea Necchi, Sebastiano Buti
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology. Immunotherapy (2021)
Roberta Minari, Francesco Bonatti, Giulia Mazzaschi, Alessandra Dodi, Francesco Facchinetti, Francesco Gelsomino, Gloria Cinquegrani, Anna Squadrilli, Paola Bordi, Sebastiano Buti, Melissa Bersanelli, Alessandro Leonetti, Agnese Cosenza, Leonarda Ferri, Elena Rapacchi, Federico Quaini, Andrea Ardizzoni, Marcello Tiseo
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors. Tumori (2021)